156 related articles for article (PubMed ID: 34582263)
1. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
Konrad-Martin D; O'Connell Bennett K; Garinis A; McMillan GP
Am J Audiol; 2021 Oct; 30(3S):870-886. PubMed ID: 34582263
[TBL] [Abstract][Full Text] [Related]
2. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).
Konrad-Martin D; Reavis KM; McMillan G; Helt WJ; Dille M
J Rehabil Res Dev; 2014; 51(1):81-100. PubMed ID: 24805896
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
4. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.
Konrad-Martin D; Poling GL; Garinis AC; Ortiz CE; Hopper J; O'Connell Bennett K; Dille MF
Int J Audiol; 2018 Sep; 57(sup4):S3-S18. PubMed ID: 29157038
[TBL] [Abstract][Full Text] [Related]
5. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.
Knight KR; Chen L; Freyer D; Aplenc R; Bancroft M; Bliss B; Dang H; Gillmeister B; Hendershot E; Kraemer DF; Lindenfeld L; Meza J; Neuwelt EA; Pollock BH; Sung L
J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095
[TBL] [Abstract][Full Text] [Related]
6. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.
Dille MF; McMillan GP; Helt WJ; Konrad-Martin D; Jacobs P
J Am Acad Audiol; 2015 Oct; 26(9):750-60. PubMed ID: 26415968
[TBL] [Abstract][Full Text] [Related]
7. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.
Paken J; Govender CD; Pillay M; Sewram V
BMC Health Serv Res; 2022 Jun; 22(1):791. PubMed ID: 35717191
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
10. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
Paken J; Govender CD; Sewram V
BMC Womens Health; 2017 Dec; 17(1):129. PubMed ID: 29228931
[TBL] [Abstract][Full Text] [Related]
11. Insight into the current practice of ototoxicity monitoring during cisplatin therapy.
Santucci NM; Garber B; Ivory R; Kuhn MA; Stephen M; Aizenberg D
J Otolaryngol Head Neck Surg; 2021 Mar; 50(1):19. PubMed ID: 33766142
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
13. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
[TBL] [Abstract][Full Text] [Related]
14. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
16. Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists: A Survey-Based Study in a Single Italian Medical Center.
Gambacorta V; Orzan E; Faralli M; Gullà M; Lapenna R; Baietta I; De Angelis V; Ricci G
Audiol Res; 2023 Oct; 13(5):779-790. PubMed ID: 37887850
[TBL] [Abstract][Full Text] [Related]
17. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
Moore B; Sheets G; Doss J; Umrigar A; Norman M; Fang Z; Prasad P; Musso A; Clay S; Tsien F
Am J Audiol; 2023 Sep; 32(3):657-664. PubMed ID: 37532243
[TBL] [Abstract][Full Text] [Related]
18. Audiologists' perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey.
Konrad-Martin D; Polaski R; DeBacker JR; Theodoroff SM; Garinis A; Lacey C; Johansson K; Mannino R; Milnes T; Hungerford M; Clark KD
J Cancer Surviv; 2023 Feb; 17(1):69-81. PubMed ID: 36729345
[TBL] [Abstract][Full Text] [Related]
19. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.
Garinis AC; Cornell A; Allada G; Fennelly KP; Maggiore RJ; Konrad-Martin D
Int J Audiol; 2018 Sep; 57(sup4):S19-S24. PubMed ID: 28978238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
